Document is current
Any future updates will be listed below
-
Authors
Brumbaugh, Jane E.
Bell, Edward F.
Hirsch, Shawn C.
Crenshaw, Emma G.
DeMauro, Sara B.
Adams-Chapman, Ira S.
Lowe, Jean R.
Natarajan, Girija
Wyckoff, Myra H.
Vohr, Betty R.
Colaizy, Tarah T.
Harmon, Heidi M.
Watterberg, Kristi L.
Hintz, Susan R.
,
- License Information
-
More Information
Article History
Received: 30 March 2021
Revised: 15 September 2021
Accepted: 27 September 2021
First Online: 22 October 2021
Competing interests
: The authors have no potential or perceived conflicts of interest to disclose relevant to this manuscript. None of the authors report any commercial, proprietary, or financial interest in any of the products described in this article. NICHD is the sponsor of the study and holds the investigational new drug (IND) application. Abbott Nutrition Division, Abbott Laboratories, Columbus, OH, provided the <i>myo</i>-inositol product. They had no role in the design of the trial; the analyses, interpretation, or writing of the manuscript; or the decision to submit the manuscript for publication. They provided on-site monitoring to assist in quality assurance of the data collection.
: This study was a secondary analysis of the “Inositol to Reduce Retinopathy of Prematurity” trial (NCT01954082); informed consent was required for participation in this trial.
